Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ:ASPI) announced a Proposed Merger of its wholly owned subsidiary Noble Africa with a subsidiary of ENDRA Life Sciences (NASDAQ:NDRA). The surviving company plans to be renamed Noble Africa and apply to list on Nasdaq under the ticker NOBA.
In connection with the Proposed Transactions, Noble Africa has secured commitments for a concurrent private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes and about $30 million from other investors, to support development of Renergen’s Virginia Gas Project.
ASP Isotopes (NASDAQ: ASPI)/b) announced that Tetra4, developer of the Virginia Gas Project in South Africa, signed its first five-year take-or-pay contract to supply contained helium to an Asian industrial gases company at an initial base price above
ASP Isotopes (NASDAQ: ASPI) restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, which have operated for over three weeks at target enrichment levels.
Engineering enhancements to non-core components are planned for remaining stages, supporting three U.S. contracts and expected initial commercial shipments in Q3 2026.
ASP Isotopes (NASDAQ: ASPI) announced that subsidiary Quantum Leap Energy signed a non-binding MOU with a European advanced nuclear reactor developer to assess long-term HALEU fuel supply. The framework covers uranium feedstock supply, conversion, enrichment above 10% U-235, potential deconversion, and deliveries potentially starting in 2028, with the MOU running through 2030.
Quantum Leap Energy (ASPI) appointed Dr. Peter S. Fiske to its Strategic Advisory Board on May 6, 2026. Dr. Fiske brings experience in technology commercialization, advanced materials, and government partnerships, including leadership of the DOE-backed National Alliance for Water Innovation.
The appointment follows QLE's recent SAB formation, CTO Nate Salpeter hire, and a strategic collaboration with the University of Bristol on a lithium laser research facility.
Skyline Builders Group Holding Ltd and Cove Kaz Capital Group LLC (ASPI) announced a transaction to combine into Kaz Resources Inc. (expected Nasdaq: KAZR) to develop Kazakhstan critical-minerals projects.
Key facts: acquisition closed April 29, 2026; largest undeveloped tungsten resource of 1.4 million tonnes WO3; expected production 12,000 mtpa; EXIM and DFC issued LOIs totaling $1.6 billion; estimated development cost $1.1 billion.
ASP Isotopes (NASDAQ: ASPI) provided a business update on April 13, 2026 outlining near-term commercial milestones, operational progress, and financials. The company expects first commercial shipments across Silicon-28, Carbon-14, and Yb-176 in 2026, and Helium Phase 1 nameplate capacity in Q3 2026. Cash and equivalents were $333 million as of December 31, 2025, product revenue was $5.7 million in 2025, and a long-term EBITDA target of greater than $300 million in 2031 was reiterated.
ASP Isotopes (NASDAQ: ASPI) will host a business update conference call and webcast on Monday, April 13, 2026 at 8:00 AM ET, led by Paul Mann, Executive Chairman and CEO.
Dial-in numbers and Conference ID 5073116 are provided for live participation; a replay will be available at www.aspisotopes.com roughly three hours after the call concludes.
ASP Isotopes (NASDAQ: ASPI) said a UK subsidiary of Quantum Leap Energy has begun a strategic collaboration with the University of Bristol to design a lithium laser enrichment research facility. The University will lead a site-agnostic feasibility and design study in an estimated four-month initial phase, including safety reviews and RIBA Stage 4 technical design.
Subject to a positive feasibility assessment, parties intend to proceed to construction at a suitable Bristol site; work was developed in consultation with UK regulators including the Department for Energy Security and Net Zero and the Office for Nuclear Regulation.
ASP Isotopes (NASDAQ: ASPI) completed drilling for Phase 1 of the Renergen Helium Project about four months ahead of schedule on March 23, 2026. New wells delivered gas flows up to 16x prior wells and the project has reached Phase 1 nameplate flow, reducing execution risk.
ASP expects Phase 1 to produce 2,500 GJ/day LNG and 58 MCF/day helium, and Phase 2 to target 34,000 GJ/day LNG and 895 MCF/day helium after a 44-month build.